Yao Ma1,2, Min He2,3, Li-Sha Hou1, Shen Xu2,4, Zhi-Xin Huang5, Na Zhao6, Yan Kang7,8, Ji-Rong Yue9,10, Chenkai Wu11. 1. Department of Geriatrics and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China. 2. COVID-19 Medical Assistance Teams (Hubei) of West China Hospital, Sichuan University, Chengdu, Sichuan Province, China. 3. Department of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China. 4. Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China. 5. Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China. 6. Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China. 7. COVID-19 Medical Assistance Teams (Hubei) of West China Hospital, Sichuan University, Chengdu, Sichuan Province, China. kangyan@scu.edu.cn. 8. Department of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China. kangyan@scu.edu.cn. 9. Department of Geriatrics and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China. yuejirong11@hotmail.com. 10. COVID-19 Medical Assistance Teams (Hubei) of West China Hospital, Sichuan University, Chengdu, Sichuan Province, China. yuejirong11@hotmail.com. 11. Global Health Research Center, Duke Kunshan University, Suzhou, Jiangsu Province, China.
Abstract
BACKGROUND: Since the outbreak of COVID-19, it has been documented that old age and underlying illnesses are associated with poor prognosis among COVID-19 patients. However, it is unknown whether sarcopenia, a common geriatric syndrome, is associated with poor prognosis among older COVID-19 patients. The aim of our prospective cohort study is to investigate the association between sarcopenia risk and severe disease among COVID-19 patients aged ≥60 years. METHOD: A prospective cohort study of 114 hospitalized older patients (≥60 years) with confirmed COVID-19 pneumonia between 7 February, 2020 and 6 April, 2020. Epidemiological, socio-demographic, clinical and laboratory data on admission and outcome data were extracted from electronic medical records. All patients were assessed for sarcopenia on admission using the SARC-F scale and the outcome was the development of the severe disease within 60 days. We used the Cox proportional hazards model to identify the association between sarcopenia and progression of disease defined as severe cases in a total of 2908 person-days. RESULT: Of 114 patients (mean age 69.52 ± 7.25 years, 50% woman), 38 (33%) had a high risk of sarcopenia while 76 (67%) did not. We found that 43 (38%) patients progressed to severe cases. COVID-19 patients with higher risk sarcopenia were more likely to develop severe disease than those without (68% versus 22%, p < 0.001). After adjustment for demographic and clinical factors, higher risk sarcopenia was associated with a higher hazard of severe condition [hazard ratio = 2.87 (95% CI, 1.33-6.16)]. CONCLUSION: We found that COVID-19 patients with higher sarcopenia risk were more likely to develop severe condition. A clinician-friendly assessment of sarcopenia could help in early warning of older patients at high-risk with severe COVID-19 pneumonia.
BACKGROUND: Since the outbreak of COVID-19, it has been documented that old age and underlying illnesses are associated with poor prognosis among COVID-19patients. However, it is unknown whether sarcopenia, a common geriatric syndrome, is associated with poor prognosis among older COVID-19patients. The aim of our prospective cohort study is to investigate the association between sarcopenia risk and severe disease among COVID-19patients aged ≥60 years. METHOD: A prospective cohort study of 114 hospitalized older patients (≥60 years) with confirmed COVID-19 pneumonia between 7 February, 2020 and 6 April, 2020. Epidemiological, socio-demographic, clinical and laboratory data on admission and outcome data were extracted from electronic medical records. All patients were assessed for sarcopenia on admission using the SARC-F scale and the outcome was the development of the severe disease within 60 days. We used the Cox proportional hazards model to identify the association between sarcopenia and progression of disease defined as severe cases in a total of 2908 person-days. RESULT: Of 114 patients (mean age 69.52 ± 7.25 years, 50% woman), 38 (33%) had a high risk of sarcopenia while 76 (67%) did not. We found that 43 (38%) patients progressed to severe cases. COVID-19patients with higher risk sarcopenia were more likely to develop severe disease than those without (68% versus 22%, p < 0.001). After adjustment for demographic and clinical factors, higher risk sarcopenia was associated with a higher hazard of severe condition [hazard ratio = 2.87 (95% CI, 1.33-6.16)]. CONCLUSION: We found that COVID-19patients with higher sarcopenia risk were more likely to develop severe condition. A clinician-friendly assessment of sarcopenia could help in early warning of older patients at high-risk with severe COVID-19 pneumonia.
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: Edward M Castillo; Deborah Goodman-Gruen; Donna Kritz-Silverstein; Deborah J Morton; Deborah L Wingard; Elizabeth Barrett-Connor Journal: Am J Prev Med Date: 2003-10 Impact factor: 5.043
Authors: Gisele Barbosa de Aguiar; Keila Fernandes Dourado; Maria Izabel Siqueira de Andrade; Ivanildo Ribeiro Domingos Júnior; João Araújo Barros-Neto; Sandra Mary Lima Vasconcelos; Marina de Moraes Vasconcelos Petribú; Cláudia Mota Dos Santos; Mayana Wanessa Santos de Moura; Claudiane Barbosa de Aguiar; Maria Isabela Xavier Campos; Emerson Rogério Costa Santiago; José Hélio Luna da Silva; Shirley Kelly Dos Santos Simões; Anna Carolina de Melo Rodrigues; José Carlos Domingues de França Filho; Natália Mayara Menezes de Souza; Thayná Menezes Santos Journal: Exp Gerontol Date: 2022-09-05 Impact factor: 4.253